Today news
The same in other media
Glenmark to start trial of favipiravir combo drug for moderate covid-19 symptoms
Reading now: 688
NEW DELHI: Glenmark Pharmaceuticals Ltd on Tuesday announced that it will soon start a study to test the combined efficacy of two antiviral drugs--favipiravir and umifenovir--as a potential covid-19 treatment strategy.
While the company is already conducting a trial of favipiravir on mild-to-moderate covid-19 symptoms, the combination drug is aimed at moderate infection in hospital settings.
In its trials involving only favipiravir, the company has so far randomised 30 patients of the 150 it plans to enroll. As part of the 158-patient randomized, open-label study of the drug combination, called the ‘FAITH’ trial, the Mumbai-based pharmaceutical firm will compare the efficacy of the combination drug against just favipiravir over a 14-day
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|